secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVANOS MEDICAL, INC. (AVNS)
CIK:        0001606498
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001606498-24-000016
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avanos Medical Q4 net sales $173.3M (-4.6% YoY); 2024 outlook $685-$705M revenue, adj. EPS $1.30-$1.45
--------------------------------------------------------------------------------

- Q4 net sales $173.3M (-4.6% YoY); full-year net sales $673.3M (-1.6%) on lower HA sales.
- Q4 GAAP diluted EPS $0.24 (vs $0.21); adjusted EPS $0.36 (vs $0.45). Full-year GAAP loss $(0.21) (vs $0.46 EPS); adjusted EPS $1.03 (vs $1.00).
- Free cash flow for 2023 was $14.6M, down from $71.6M in 2022; Q4 outflow $3.4M.
- Completed sale of respiratory health business (Oct 2) and acquired Diros Technology (July 24) to focus on Pain Management and Digestive Health.
- 2024 guidance: net sales $685-$705M (organic growth 3%-6%), adj. gross margin 59.5%-60.5%, adj. diluted EPS $1.30-$1.45.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1606498/000160649824000016/0001606498-24-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1606498/000160649824000016/avns-20240220.htm
  HTML page:      https://secwatch.observer/filing/0001606498-24-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer